Anvimo 240mg Tablet
₹23,432.80
Uses of Anvimo 240mg Tablet
Anvimo 240mg Tablet is FDA-approved for the prevention of cytomegalovirus (CMV) infection in adult patients
Product Description
Introduction of Anvimo 240mg Tablet
Anvimo 240mg Tablet is an antiviral medication containing letermovir as its active ingredient. It belongs to the pharmacological class of antiviral agents and is specifically classified under cytomegalovirus (CMV) DNA terminase inhibitors. Anvimo 240mg Tablet is primarily used to prevent cytomegalovirus (CMV) infection in patients who have recently undergone an allogeneic hematopoietic stem cell transplant (HSCT) and are at a higher risk of CMV reactivation.
Anvimo 240mg Tablet works by inhibiting the CMV DNA terminase complex, which is crucial for viral replication. It is typically prescribed for CMV-seropositive adult patients post-transplant to reduce the likelihood of viral complications. However, the medication is not a treatment for existing CMV infections.
Patients taking this medication should follow strict safety precautions. It is contraindicated in individuals with known hypersensitivity to letermovir or any of its excipients. Additionally, it is not recommended for use with certain medications due to serious drug interactions. Healthcare professionals advise caution in pregnant or breastfeeding women, individuals with liver impairment, and those consuming alcohol.
Therapeutic Effects of Anvimo Tablet
Anvimo 240mg Tablet functions by blocking the CMV DNA terminase complex, a key component required for viral replication. Unlike conventional antiviral drugs that target DNA polymerase, this medication disrupts viral DNA processing and packaging, ultimately preventing the virus from multiplying and spreading in the body.
By stopping CMV replication early in the process, this drug significantly lowers the risk of CMV disease in transplant recipients. The unique mechanism of action makes it highly effective while reducing the likelihood of cross-resistance seen with other CMV treatments. Due to its targeted action, it is well tolerated with a lower risk of severe toxicity compared to older antiviral medications.
Interaction of Anvimo 240mg Tablet with other drugs
Serious drug interactions can alter the effectiveness of Anvimo 240mg Tablet or increase the risk of side effects. Patients should inform their doctor about all medications, including herbal and over-the-counter drugs, before starting this medication.
Notable Drug Interactions:
- Immunosuppressants (e.g., Cyclosporine, Tacrolimus, Sirolimus): Letermovir can increase blood levels of these drugs, requiring dose adjustments.
- Statins (e.g., Simvastatin, Atorvastatin): Increased risk of myopathy or rhabdomyolysis when taken together. Avoid co-administration or monitor closely.
- Anticonvulsants (e.g., Phenytoin, Carbamazepine): May reduce Anvimo 240mg Tablet effectiveness, requiring alternative options.
- Rifampin and St. John’s Wort: These reduce drug efficacy and should be avoided.
- Oral Contraceptives: Letermovir may lower the effectiveness of hormonal birth control, necessitating additional contraceptive methods.
Always consult a doctor before combining this medication with others.
How to consume Anvimo Tablet
The usual recommended dosage of Anvimo Tablet for CMV prophylaxis is 480 mg once daily. However, if taken in combination with cyclosporine, the dose is reduced to 240 mg daily to prevent excessive drug levels. This medication is available in oral tablets and intravenous (IV) infusion forms. Oral tablets should be swallowed whole with or without food, while the IV infusion must be administered under medical supervision to ensure proper dosing and monitoring.
Safety Advice for Anvimo Tablet
Breast Feeding
It is unknown whether Anvimo Tablet passes into breast milk. A healthcare provider should assess whether to discontinue breastfeeding or the medication.
Alcohol
Alcohol can increase liver toxicity and should be avoided during treatment.
Liver
Patients with severe liver impairment should use caution, as Anvimo Tablet is metabolised in the liver. Dose adjustments may be required.
Lungs
No major respiratory effects have been reported. Patients with existing lung conditions can take Anvimo Tablet under medical guidance.
Driving
Anvimo Tablet does not impair alertness or cognitive function. Patients can safely drive and operate machinery unless experiencing dizziness.
Pregnancy
There is limited human data on Anvimo Tablet during pregnancy. It should only be used if the benefits outweigh the potential risks to the fetus.
Side Effects of Anvimo Tablet
Common Side Effects:
- Nausea
- Fatigue
- Headache
- Diarrhea
- Abdominal pain
Serious Side Effects:
- Irregular heartbeat
- Swelling in legs or feet
- Unexplained bleeding or bruising
- Severe allergic reactions (rash, breathing difficulty)





Reviews
There are no reviews yet.